Transparent hospice medication management is an approach to pharmacy pricing and reporting where a hospice organization can see the actual cost of every medication and delivery, with no hidden markup baked into the price. Transparency isn't a pricing feature bolted onto a model. It's a structural choice about how a pharmacy partner makes money. BetterRX builds transparent, pass-through pricing into The Better Way to Manage Hospice Medications from the ground up.
The Question CFOs Are Actually Asking
When a CFO or CEO asks whether a hospice's medication management is transparent, they're usually asking something more specific than it sounds: can I see what we're actually paying for a medication and its delivery, separate from whatever margin the pharmacy partner is keeping? In a lot of pharmacy relationships, the honest answer is no. The invoice shows a total. It doesn't show the split.
That gap matters more in hospice than almost anywhere else in healthcare, because the hospice organization itself bears the medication cost under the Medicare Hospice Benefit's per-diem structure, rather than passing that cost to an outside insurer. A hidden spread isn't an abstract inefficiency. It's a direct hit to the hospice's own margin, dollar for dollar.
Transparent vs. Spread-Based: What Actually Differs
Spread-based pricing
The pharmacy partner buys a medication at one price and bills the hospice at a higher price, keeping the difference as margin. The hospice sees a total cost but not the underlying breakdown, which makes it difficult to know whether a price is fair or to audit it over time.
Transparent, pass-through pricing
The hospice sees the actual cost of the medication and the actual delivery cost, with the pharmacy partner's compensation structured separately and visibly, rather than folded invisibly into the medication price itself.
Real-time visibility vs. retrospective reporting
Transparency also has a timing dimension. A cost report that arrives weeks after the spending decision was made can explain what happened, but it can't help a team change a decision that's already been repeated a dozen times by the time the report lands.
Why This Matters Beyond the Finance Team
Transparent medication management isn't purely a CFO concern, even though CFOs are usually the ones pushing hardest for it. Clinical leaders benefit from the same visibility, since knowing the real cost of a medication at the point of order, alongside a lower-cost clinically appropriate alternative, lets a nurse or prescriber make a cost-aware decision without slowing down care. Operations leaders benefit because transparent pricing is easier to standardize and audit consistently across multiple locations than a spread-based model that can vary site to site.
1. Can the hospice see the actual cost of a medication, separate from any markup?
2. Is delivery pricing itemized and visible, rather than folded into a single opaque total?
3. Is cost information available at the point of order, or only in a delayed monthly report?
4. Does the pricing model hold up the same way across every location, or does it vary by site?
How BetterRX Builds Transparency Into the Model
BetterRX uses transparent, pass-through pharmacy pricing and does not profit from medication or delivery markups. Incentives stay aligned with the hospice: better care, lower unnecessary costs, and medications reaching patients as quickly as possible. Intelligent Medication Management pairs that pricing structure with real-time cost intelligence, surfacing pricing and lower-cost alternatives at the moment of ordering rather than in a delayed report, and Actionable Reporting & Analytics gives finance and operations leaders a live view of per-patient-day (PPD) performance instead of last month's numbers.
The pharmacy side of the relationship bears this out directly. In a 2024 Qualtrics survey of more than 100 independent pharmacies, 96% said they prefer BetterRX to traditional hospice PBMs, and 94% said BetterRX speeds order fulfillment, a meaningful signal that a transparent, aligned-incentive model works well on both sides of the relationship, not just for the hospice.
"The analytics have been very useful and have helped us reduce unnecessary costs."
- VOC respondent
That kind of outcome is what transparency is supposed to produce: not just a clearer invoice, but decisions made differently because the real cost was visible in time to act on it. It's the difference between a finance team that finds out about a cost pattern after a quarter has already closed and one that catches it while there's still time to change course.
What Transparency Doesn't Mean
It's worth being precise about what transparent medication management is not. It isn't a promise that medications will always be cheap, and it isn't a guarantee that every cost will trend downward every month. Medication prices genuinely fluctuate for reasons outside any pharmacy partner's control, including manufacturer pricing changes and supply disruptions. What transparency actually promises is narrower and more useful: that the hospice can see why a cost is what it is, and can trust that the number reflects a real, disclosed cost rather than an invisible markup layered on top of it.
This distinction matters because a hospice that expects transparency to mean permanently falling costs will eventually feel misled by ordinary market movement. A hospice that understands transparency as visibility, not a price ceiling, is better equipped to use that visibility for what it's actually good for: catching real cost drivers, forecasting accurately, and holding a pharmacy partner accountable to the pricing structure it agreed to.
Making Transparency Part of How the Organization Operates
Transparent medication management works best when it's treated as an ongoing operating standard, not a one-time contract term negotiated at signing. Reviewing real-time cost data on a regular cadence, tying it to Predictable PPD goals, and making sure every location has the same visibility keeps transparency from quietly eroding as an organization grows or adds new sites.
Common Mistakes to Avoid When Evaluating Transparency Claims
Hospice leaders evaluating a pharmacy partner's transparency claims run into a few predictable traps. Recognizing them ahead of time makes it easier to ask the right follow-up question instead of taking a claim at face value.
Accepting the word "transparent" without a cost breakdown. Any partner can describe its pricing as transparent. The only real proof is whether the hospice can see the medication cost and delivery cost, separated out, on request.
Confusing a detailed invoice with a transparent one. An invoice with many line items can still hide a markup inside one of those line items. Detail and transparency are not the same thing.
Assuming a lower total price means transparent pricing. A spread-based partner can sometimes quote a lower headline number while still keeping an undisclosed margin inside it. Price alone doesn't reveal how the number was built.
Treating a one-time contract review as sufficient. Pricing structures can shift over time as a vendor renegotiates its own supplier contracts. Revisiting the transparency question annually, not just at signing, keeps the standard from quietly slipping.
Frequently Asked Questions
-
It's an approach to pharmacy pricing and reporting where a hospice can see the actual cost of every medication and delivery, with no hidden markup built into the price.
-
Transparent, pass-through pricing shows the hospice the actual medication and delivery cost. Spread-based pricing includes a hidden margin that isn't visible or easy to audit.
-
Because the hospice itself bears the medication cost under the Medicare Hospice Benefit's per-diem structure, a hidden spread is a direct hit to the organization's own margin.
-
No. Clinical and operations leaders also benefit, since real-time cost visibility supports cost-aware clinical decisions and easier standardization across multiple locations.
-
Ask whether the actual cost of a medication and its delivery are itemized and visible, or whether the invoice only shows a single, unexplained total.
-
It can. Seeing cost information at the point of order, rather than in a delayed report, gives teams a chance to correct a pattern before it repeats rather than only explaining it afterward.
-
Not really. Either the hospice can see the actual medication and delivery cost behind a medication, or it can't. Partial disclosure, such as showing delivery cost but not medication cost, still leaves room for an undisclosed markup elsewhere.
BetterRX
